Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

First Posted Date
2003-01-27
Last Posted Date
2023-06-18
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
1929
Registration Number
NCT00002514
Locations
🇺🇸

Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States

🇺🇸

MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States

🇺🇸

Swedish Medical Center, Englewood, Colorado, United States

and more 91 locations

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

First Posted Date
2003-01-27
Last Posted Date
2020-12-10
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
125
Registration Number
NCT00005797
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2016-02-03
Lead Sponsor
AIDS Malignancy Consortium
Target Recruit Count
19
Registration Number
NCT00041327
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2014-08-01
Lead Sponsor
Children's Oncology Group
Target Recruit Count
69
Registration Number
NCT00002941
Locations
🇺🇸

All Children's Hospital, St. Petersburg, Florida, United States

🇺🇸

Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States

🇺🇸

Children's Hospital Central California, Madera, California, United States

and more 231 locations

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1
Completed
Conditions
Recurrent Adult Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Childhood Non-Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
T-Cell Chronic Lymphocytic Leukemia
T-Cell Prolymphocytic Leukemia
Recurrent Childhood Hodgkin Lymphoma
Interventions
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Autologous Lymphocytes
Radiation: Total-Body Irradiation
First Posted Date
2003-01-27
Last Posted Date
2020-01-29
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
76
Registration Number
NCT00005803
Locations
🇺🇸

Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

🇺🇸

LDS Hospital, Salt Lake City, Utah, United States

🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

and more 2 locations

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-02-04
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT00007982
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2023-09-01
Lead Sponsor
University of Nebraska
Target Recruit Count
50
Registration Number
NCT00006695
Locations
🇺🇸

UNMC Eppley Cancer Center at University of Nebraska Medical Center, Omaha, Nebraska, United States

Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia

First Posted Date
2003-01-27
Last Posted Date
2023-08-21
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
105
Registration Number
NCT00039130
Locations
🇺🇸

University of Illinois Cancer Center, Chicago, Illinois, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

and more 28 locations

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

First Posted Date
2003-01-27
Last Posted Date
2023-08-03
Lead Sponsor
Children's Oncology Group
Target Recruit Count
587
Registration Number
NCT00006734
Locations
🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

University of Illinois Medical Center, Chicago, Illinois, United States

and more 235 locations

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

First Posted Date
2003-01-27
Last Posted Date
2013-12-19
Lead Sponsor
Medical Research Council
Registration Number
NCT00005863
Locations
🇬🇧

Birmingham Heartlands Hospital, Birmingham, England, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy